June 2026

In a major advancement in the fight against antibiotic-resistant infections, the U.S. Food and Drug Administration (FDA) has approved Utebzi (tebipenem pivoxil hydrobromide), the first oral carbapenem antibiotic for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. The approval provides patients and healthcare providers with a long-awaited oral alternative to intravenous carbapenem therapy.

In a significant step toward improving access to influenza treatment, the U.S. Food and Drug Administration (FDA) has approved the first generic version of baloxavir marboxil tablets, a single-dose antiviral medicine used for the treatment and prevention of influenza. The approval comes just before the start of the 2026-27 flu season and is expected to provide patients with a more affordable treatment option.